CN1399554A - 抑制粘连形成的方法和组合物 - Google Patents

抑制粘连形成的方法和组合物 Download PDF

Info

Publication number
CN1399554A
CN1399554A CN00816148A CN00816148A CN1399554A CN 1399554 A CN1399554 A CN 1399554A CN 00816148 A CN00816148 A CN 00816148A CN 00816148 A CN00816148 A CN 00816148A CN 1399554 A CN1399554 A CN 1399554A
Authority
CN
China
Prior art keywords
antagonist molecules
compositions
monoclonal antibody
molecules
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00816148A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·克雷斯
B·莱西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Scripps Research Institute
Original Assignee
University of North Carolina at Chapel Hill
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Scripps Research Institute filed Critical University of North Carolina at Chapel Hill
Publication of CN1399554A publication Critical patent/CN1399554A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN00816148A 1999-09-23 2000-09-22 抑制粘连形成的方法和组合物 Pending CN1399554A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
US09/405522 1999-09-23

Publications (1)

Publication Number Publication Date
CN1399554A true CN1399554A (zh) 2003-02-26

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00816148A Pending CN1399554A (zh) 1999-09-23 2000-09-22 抑制粘连形成的方法和组合物

Country Status (9)

Country Link
EP (1) EP1223962A4 (enExample)
JP (1) JP2003509468A (enExample)
KR (1) KR20020048941A (enExample)
CN (1) CN1399554A (enExample)
AU (1) AU781442B2 (enExample)
BR (1) BR0014222A (enExample)
CA (1) CA2384812A1 (enExample)
MX (1) MXPA02003079A (enExample)
WO (1) WO2001021196A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
EP3485921B1 (en) 2016-07-13 2025-07-23 Mochida Pharmaceutical Co., Ltd. Adhesion-preventing composition
CN111936175A (zh) * 2018-01-15 2020-11-13 持田制药株式会社 防粘连用组合物
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
EP4126957A4 (en) * 2020-03-31 2024-07-24 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP1017389A1 (en) * 1997-08-25 2000-07-12 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
EP1223962A4 (en) 2004-01-21
MXPA02003079A (es) 2004-04-21
BR0014222A (pt) 2003-02-25
CA2384812A1 (en) 2001-03-29
KR20020048941A (ko) 2002-06-24
JP2003509468A (ja) 2003-03-11
WO2001021196A1 (en) 2001-03-29
AU781442B2 (en) 2005-05-26
AU7985000A (en) 2001-04-24
EP1223962A1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
JP3333507B2 (ja) 創傷治療
US20130344129A1 (en) Inflammation-regulating compositions and methods
JP7658914B2 (ja) コラーゲン・ペプチド系医薬組成物および該医薬組成物を含む医療器具
US11529424B2 (en) Synthetic bioconjugates
US20090177228A1 (en) Coated suture thread and production thereof
AU2015306811A1 (en) Extracellular matrix compositions
KR20220151029A (ko) 콜라겐 펩티드-계 의약 조성물 및 이의 생산 장비 및 방법 및 사용
WO2016061145A1 (en) Synthetic proteoglycans for preventing tissue adhesion
JP2000503318A (ja) 治癒過程の調節
Okada et al. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor
CN1399554A (zh) 抑制粘连形成的方法和组合物
JP5646507B2 (ja) 創傷、傷跡、および手術後の癒着形成を治療するためのヒアルロン酸含有組成物
CN102405050B (zh) 抑制细胞增殖和手术粘连的方法和组合物
EP3261672B1 (en) Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof
JP5194207B2 (ja) 腹腔内グルタミンによる術後癒着形成の減少
AU1843495A (en) Fibrin-specific antibody for use as an antithrombotic agent
JP2006522140A (ja) 線維症の治療用ポリマー薬剤
Tran et al. An in vivo evaluation of a chondroitin sulfate solution to prevent postoperative intraperitoneal adhesion formation
Bakkum et al. Postsurgical adhesion formation and prevention–recent developments with regard to the consecutive stages in adhesion formation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication